Merck a leading science and technology company today announced new realworld data that continue to reinforce the JAVELIN Bladder regimen of firstline platinumbased chemotherapy followed by BAVENCIO avelumab maintenance as a standard of care for eligible patients with locally advanced or metastatic urothelial carcinoma UC who do not progress on firstline chemotherapy.
Merck: Multiple New Analyses Reinforce the Role of BAVENCIO (avelumab) First-Line Maintenance as a Standard of Care in Patients with Locally Advanced or Metastatic Urothelial Carcinoma finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Multiple New Analyses Reinforce the Role of BAVENCIO® (avelumab) First-Line Maintenance as a Standard of Care in Patients with Locally Advanced or Metastatic Urothelial Carcinoma streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.